(15) SEGEMENT REPORTING

12 Months Ended

Dec. 31, 2011

Segment Reporting Disclosure [Text Block]

(15) SEGMENT REPORTING

The Company has two operating segments: the sale of blood volume analysis equipment and related services, and cryobanking services which encompasses blood and semen storage and related services. In addition, the Company reports an additional segment, Investment Activity, although it is not deemed to be an operating segment. 

The following tables summarize the results of each segment described above for the years ended December 31, 2011 and December 31, 2010.

December 31, 2011

	Equipment Sales and Related Services			Cryobanking and Related Services			Investment Activity			Total
Revenues	$	1,125,249		$	321,096		$	—		$	1,446,345
Expenses
Cost of Sales		616,063			36,448			—			652,511
Research and Development		2,508,657			197,295			—			2,705,952
Selling, general and administrative expenses		3,219,204			655,092			—			3,874,296
Total Costs and Expenses		6,343,924			888,835			—			7,232,759
Operating Loss		(5,218,675	)		(567,739	)		—			(5,786,414	)
Investment income, net
Dividends		—			—			2,237,734			2,237,734
Gain on sale of securities, net		—			—			33,189			33,189
Mark to market of short positions		—			—			(8,501,859	)		(8,501,859	)
Administrative expenses relating to portfolio investments		—			—			(153,816	)		(153,816	)
Total investment loss, net		—			—			(6,384,752)			(6,384,752)
Interest expense, net of interest income of $6,425		(32,552	)		—			(136,371	)		(168,923	)
Other income		12,374			—			—			12,374
Loss before income taxes		(5,238,853	)		(567,739	)		(6,521,123)			(12,327,715)
Income tax expense (benefit)		115,754			470			(5,258,300)			(5,142,076)
Net loss	$	(5,354,607	)	$	(568,209	)	$	(1,262,823)		$	(7,185,639)
Total Assets	$	6,710,535		$	131,187		$	78,883,139		$	85,724,861

December 31, 2010

	Equipment Sales and Related Services			Cryobanking and Related Services			Investment Activity			Total
Revenues	$	1,242,264		$	336,993		$	—		$	1,579,257
Expenses
Cost of Sales		691,786			35,864			—			727,650
Research and Development		2,826,068			215,572			—			3,041,640
Selling, general and administrative expenses		2,750,626			718,452			—			3,469,078
Total Costs and Expenses		6,268,480			969,888			—			7,238,368
Operating Loss		(5,026,216	)		(632,895	)		—			(5,659,111	)
Investment income, net
Dividends		—			—			2,226,198			2,226,198
Gain on sale of securities, net		—			—			13,509,318			13,509,318
Mark to market of short positions		—			—			(1,526,064	)		(1,526,064	)
Administrative expenses relating to portfolio investments		—			—			(150,675	)		(150,675	)
Total investment income, net		—			—			14,058,777			14,058,777
Interest expense, net of interest income of $1,944		(27,759	)		296			(34,213	)		(61,676	)
Other income		12,166			—			—			12,166
Income (loss) before income taxes		(5,041,809	)		(632,599	)		14,024,564			8,350,156
Income tax expense		134,760			—			3,247,132			3,381,892
Net income (loss)	$	(5,176,569	)	$	(632,599	)	$	10,777,432		$	4,968,264
Total Assets	$	4,773,411		$	163,494		$	86,258,510		$	91,195,415